Nuclear Medicine and Biology
Volume 36, Issue 7 , Pages 779-787 , October 2009

Comparison of 18F-FET and 18F-FDG PET in brain tumors

  • Dirk Pauleit

      Affiliations

    • Institute of Neuroscience and Medicine, Forschungszentrum Jülich, D-52425 Jülich, Germany
    • ,
  • Gabriele Stoffels

      Affiliations

    • Institute of Neuroscience and Medicine, Forschungszentrum Jülich, D-52425 Jülich, Germany
    • ,
  • Ansgar Bachofner

      Affiliations

    • Clinic of Nuclear Medicine, Heinrich-Heine-University, D-40001 Düsseldorf, Germany
    • ,
  • Frank W. Floeth

      Affiliations

    • Department of Neurosurgery, Heinrich-Heine-University, D-40001 Düsseldorf, Germany
    • ,
  • Michael Sabel

      Affiliations

    • Department of Neurosurgery, Heinrich-Heine-University, D-40001 Düsseldorf, Germany
    • ,
  • Hans Herzog

      Affiliations

    • Institute of Neuroscience and Medicine, Forschungszentrum Jülich, D-52425 Jülich, Germany
    • ,
  • Lutz Tellmann

      Affiliations

    • Institute of Neuroscience and Medicine, Forschungszentrum Jülich, D-52425 Jülich, Germany
    • ,
  • Paul Jansen

      Affiliations

    • Institute of Advanced Simulation, Forschungszentrum Jülich, D-52425 Jülich, Germany
    • ,
  • Guido Reifenberger

      Affiliations

    • Department of Neuropathology, Heinrich-Heine-University, D-40001 Düsseldorf, Germany
    • ,
  • Kurt Hamacher

      Affiliations

    • Institute of Neuroscience and Medicine, Forschungszentrum Jülich, D-52425 Jülich, Germany
    • ,
  • Heinz H. Coenen

      Affiliations

    • Institute of Neuroscience and Medicine, Forschungszentrum Jülich, D-52425 Jülich, Germany
    • ,
  • Karl-Josef Langen

      Affiliations

    • Institute of Neuroscience and Medicine, Forschungszentrum Jülich, D-52425 Jülich, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 2461 61 5900, +49 2461 61 8261.

Received 19 March 2009 ,Revised 16 May 2009 ,Accepted 19 May 2009.

References 

  1. Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007;48:1468–1481
  2. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778–785
  3. Goldman S, Levivier M, Pirotte B, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med. 1997;38:1459–1462
  4. Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med. 2000;41:1861–1867
  5. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432–445
  6. Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-l-tyrosine for tumor imaging. J Nucl Med. 1999;40:205–212
  7. Hamacher K, Coenen HH. Efficient routine production of the 18F-labelled amino acid O-(2-[18F]fluoroethyl)-l-tyrosine. Appl Radiat Isot. 2002;57:853–856
  8. Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F]fluoroethyl)-l-tyrosine PET combined with magnetic resonance imaging improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678–687
  9. Pöpperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging. 2004;31:1464–1470
  10. Rachinger W, Goetz C, Pöpperl G, et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery. 2005;57:505–511
  11. Floeth FW, Pauleit D, Sabel M, et al. Prognostic value of O-(2-18F-fluoroethyl)-l-tyrosine PET and MRI in low-grade glioma. J Nucl Med. 2007;48:519–527
  12. Langen KJ, Hamacher K, Weckesser M, et al. O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006;33:287–294
  13. Chung JK, Kim YK, Kim SK, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29:176–182
  14. Pirotte B, Goldman S, Massager N, et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med. 2004;45:1293–1298
  15. Van Laere K, Ceyssens S, Van Calenbergh F, et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging. 2005;32:39–51
  16. Weber W, Bartenstein P, Gross MW, et al. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med. 1997;38:802–808
  17. Bader JB, Samnick S, Moringlane JR, et al. Evaluation of L-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. Eur J Nucl Med. 1999;26:144–151
  18. Henze M, Mohammed A, Schlemmer HP, et al. PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating-characteristic analysis. J Nucl Med. 2004;45:579–586
  19. Kleihues P, Cavenee WK. World Health Organization classification of tumours. Pathology and genetics of tumours of the nervous system. Lyon, France: IARC Press; 2000;
  20. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109
  21. Floeth FW, Pauleit D, Wittsack HJ, et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-l-tyrosine and magnetic resonance spectroscopy. J Neurosurg. 2005;102:318–327
  22. Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235–238
  23. Pöpperl G, Kreth FW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34:1933–1942
  24. Meyer PT, Schreckenberger M, Spetzger U, et al. Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses. Eur J Nucl Med. 2001;28:165–174
  25. Chen W, Silverman DH, Delaloye S, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47:904–911
  26. Grosu AL, Weber WA, Franz M, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET(SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:511–519
  27. Ceyssens S, Van Laere K, de Groot T, et al. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol. 2006;27:1432–1437
  28. Schmidt D, Gottwald U, Langen KJ, et al. 3-[123I]Iodo-α-methyl-l-tyrosine uptake in cerebral gliomas: relationship to histopathological grading and prognosis. Eur J Nucl Med. 2001;28:855–861
  29. Kaim AH, Weber B, Kurrer MO, et al. (18)F-FDG and (18)F-FET uptake in experimental soft tissue infection. Eur J Nucl Med. 2002;29:648–654
  30. Spaeth N, Wyss MT, Weber B, et al. Uptake of 18F-fluorocholine, 18F-fluoroethyl-l-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence. J Nucl Med. 2004;45:1931–1938
  31. Floeth FW, Pauleit D, Sabel M, et al. Differentiation of tumorous and non-tumorous ring enhancing lesions (REL) with FET PET. J Nucl Med. 2006;47:776–782
  32. Salber D, Stoffels G, Pauleit D, et al. Differential uptake of 18F-FET and 3H-l-methionine in focal cortical ischemia. Nucl Med Biol. 2006;33:1029–1035
  33. Salber D, Stoffels G, Pauleit D, et al. Differential uptake of 18F-FET, 3H-l-methionine and 3H-deoxyglucose in brain abscesses. J Nucl Med. 2007;48:2056–2062
  34. Weckesser M, Langen KJ, Rickert CH, et al. O-(2-[18F]fluorethyl)-l-tyrosine PET in the clinical evaluation of primary brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:422–429
  35. Pöpperl G, Kreth FW, Herms J. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?. J Nucl Med. 2006;47:393–403

PII: S0969-8051(09)00130-9

doi: 10.1016/j.nucmedbio.2009.05.005

Nuclear Medicine and Biology
Volume 36, Issue 7 , Pages 779-787 , October 2009

Article Tools

* Image Usage & Resolution